Certara (NASDAQ:CERT) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Certara (NASDAQ:CERT) from a buy rating to a hold rating in a report published on Saturday morning.

A number of other brokerages have also weighed in on CERT. KeyCorp dropped their price objective on shares of Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday. Morgan Stanley lowered their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. BMO Capital Markets initiated coverage on Certara in a report on Thursday, November 13th. They issued a “market perform” rating and a $9.00 price objective on the stock. Leerink Partners upgraded Certara from a “market perform” rating to an “outperform” rating and set a $13.00 price objective for the company in a research note on Tuesday, January 6th. Finally, Barclays dropped their target price on Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $12.58.

Certara Stock Performance

CERT opened at $9.33 on Friday. Certara has a 52-week low of $8.02 and a 52-week high of $15.69. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.49 billion, a P/E ratio of 133.29 and a beta of 1.46. The firm’s 50-day moving average price is $9.11 and its 200-day moving average price is $10.56.

Certara (NASDAQ:CERT) last released its earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The company had revenue of $104.62 million during the quarter, compared to analysts’ expectations of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same period last year, the business earned $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. As a group, equities analysts anticipate that Certara will post 0.28 EPS for the current fiscal year.

Institutional Trading of Certara

Hedge funds have recently added to or reduced their stakes in the company. AdvisorNet Financial Inc purchased a new position in Certara in the second quarter valued at $25,000. First Horizon Corp acquired a new stake in shares of Certara during the 3rd quarter valued at about $30,000. Versant Capital Management Inc increased its stake in shares of Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares in the last quarter. Osaic Holdings Inc. increased its stake in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new position in Certara in the 2nd quarter worth about $59,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.